Therefore, FEN1 or DNA2 inhibitors can induce synthetic lethality with BRCA1/2 deficiency and/or with PARPi in human cancer cells (Liu et al., 2016; Mengwasser et al., 2019; Guo et al., 2020). Here, DNA2 is linked to cancer.